The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.
Category: donanemab
-
F.D.A. Delays Action on Closely Watched Alzheimer’s Drug
Eli Lilly’s donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug’s safety and efficacy.
-
Treating Alzheimer’s Very Early Offers Better Hope of Slowing Decline, Study Finds
A trial of donanemab, an experimental drug, found it modestly slowed the worsening of memory and thinking and worked better in patients at earlier stages and those under 75.